Provided is a low-molecular-weight holothurian glycosarninoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via β(1-3) and β(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group:the N-acetaminogalactose group:the fucose group is 1:(0.8-1.2):(0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups. The low-molecular-weight holothurian glycosarninoglycan of the present invention has anti-inflammation, anti-vasculopathy, anti-tumor or anti-tumor-metastasis functions, and the effect of improving learning and memory abilities, and can be used for preparing a related drug or health-care product.
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes Leurs dérivés
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
3.
LOW-MOLECULAR-WEIGHT HOLOTHURIAN GLYCOSAMINOGLYCAN AND USE THEREOF
Provided is a low-molecular-weight holothurian glycosaminoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via β(1-3) and β(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group : the N-acetaminogalactose group : the fucose group is 1 : (0.8-1.2) : (0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10%-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups. The low-molecular-weight holothurian glycosaminoglycan of the present invention has anti-inflammation, anti-vasculopathy, anti-tumor or anti-tumor-metastasis functions, and the effect of improving learning and memory abilities, and can be used for preparing a related drug or health-care product.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
4.
PIPER LAETISPICUM EXTRACT AND PREPARATION METHOD THEREFOR AND USE THEREOF
C07C 311/00 - Amides d'acides sulfoniques, c.-à-d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
C07B 63/00 - PurificationSéparation spécialement adaptée aux fins d'isolement des composés organiquesStabilisationEmploi d'additifs
The use of paederosidic acid for preparing analgesic and anti-inflammatory medicaments is provided in the present invention. Paederosidic acid provided by the present invention has good analgesic effect on both periphery and central nerves. Meanwhile, it also has good anti-inflammatory effects. Thus, it can be used alone or with other pharmaceutically acceptable components, and can be used to prepare analgesic and/or anti-inflammatory medicaments.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
Piper laetispicum C.DC. extract and the preparation method thereof as well as the application of the extract in preparing drugs, healthcare products and food additives for treating and/or preventing diseases related to monoamine transmitters such as 5-hydroxytryptamine, noradrenaline and dopamine. The extract is obtained through impregnating or percolating at normal temperature or ≦70° C., or is obtained through supercritical fluid extraction method, and in comparison with the existing reflux method, it has higher alkaloid content and higher biological activity.
A01N 65/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux contenant du matériel provenant d'algues, de lichens, de bryophytes, de champignons multicellulaires ou de plantes, ou leurs extraits
7.
PIPER LAETISPICUM EXTRACT AND PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed are a Piper laetispicum extract and a preparation method therefor and a use thereof. The Piper laetispicum extract comprises any one of sesamin, (2E, 6E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)heptadienamide, (2E, 4E)-N-isobutyl dodeca-2,4-dienamide, (2E, 4E)-N-isobutyl-15-phenyl-2, 4-dienamide, (2E, 4E, 14Z)-N-isobutyleicosane-2, 4, 14-trienamide, (2E, 4E)-N-isobutyl-13-phenyl-2, 4-dienamide or a combination of the above. The Piper laetispicum extract can prevent depression.
C07B 63/00 - PurificationSéparation spécialement adaptée aux fins d'isolement des composés organiquesStabilisationEmploi d'additifs
C07C 311/00 - Amides d'acides sulfoniques, c.-à-d. composés comportant des atomes d'oxygène, liés par des liaisons simples, de groupes sulfoniques remplacés par des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso
8.
METHOD TO PREPARE PIPER LAETISPICUM C.DC. EXTRACT, THE EXTRACT AND THE APPLICATION THEREOF
This is about a type of Piper laetispicum C.DC. extract and the preparation method thereof as well as the application of the extract in preparing drugs, healthcare products and food additives for treating and/or preventing diseases related to monoamine transmitters such as 5-hydroxytryptamine, noradrenaline and dopamine. The extract is obtained through impregnating or percolating at normal temperature or .ltoreq.70.degree.C., or is obtained through supercritical fluid extraction method, and in comparison with the existing reflux method, it has higher alkaloid content and higher biological activity.
brevets
